Fortrea (FTRE) Stock Price, News & Analysis

Company Overview

Fortrea (NASDAQ:FTRE) is a global contract development and manufacturing organization (CDMO) serving the pharmaceutical and biotechnology industries. The company delivers end-to-end solutions encompassing process development, clinical and commercial manufacturing, analytical testing and regulatory support. Fortrea’s integrated service offerings are designed to accelerate the development and supply of small-molecule and biologic therapies, helping clients navigate complex regulatory pathways and meet evolving market demands.

Fortrea’s capabilities span the full life cycle of drug development. In the small-molecule arena, the company provides synthetic chemistry, formulation development, scale-up and cGMP commercial manufacturing. For biologics, Fortrea offers cell line development, upstream and downstream processing, aseptic fill-finish and packaging services. Its analytical laboratories perform method development, stability studies and release testing, while regulatory experts guide submissions and inspections in key markets.

Formed in 2022 through the consolidation of several established CDMO platforms under the ownership of New Mountain Capital, Fortrea has rapidly expanded its global footprint. The company operates a network of facilities across North America, Europe and Asia, including major sites in the United States, Switzerland, Spain and India. This geographic reach enables Fortrea to support both early-stage clinical trials and large-scale commercial production, ensuring reliable supply chains for its customers worldwide.

Under the leadership of CEO Christopher Cline and a senior management team drawn from industry veterans, Fortrea is focused on strategic investments in capacity, technology and digital infrastructure. By leveraging its multidisciplinary expertise and flexible operating model, the company aims to deliver tailored solutions for emerging therapies, orphan drugs and blockbuster pharmaceuticals alike, reinforcing its position as a trusted partner in the life sciences sector.

Key Stats

• Today's Range: $4.40 to $4.97
• 50-Day Range: $4.06 to $6.33
• 52-Week Range: $3.97 to $28.41
• Volume: 470,419 shs
• Average Volume: 1.94 million shs
• Market Capitalization: $436.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Reduce

Fortrea Stock Analysis - MarketRank™

Fortrea scored higher than 77% of companies evaluated by MarketBeat, and ranked 217th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Reduce

Consensus Rating

Fortrea has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 12 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Fortrea has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 150.98%

Earnings Growth

Earnings for Fortrea are expected to grow by 150.98% in the coming year, from $0.51 to $1.28 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fortrea is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fortrea is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Fortrea has a PEG Ratio of 0.36. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Fortrea has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.58% of the float of Fortrea has been sold short.

Short Interest Ratio / Days to Cover

Fortrea has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Fortrea has recently increased by 11.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fortrea does not currently pay a dividend.

Dividend Growth

Fortrea does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.58% of the float of Fortrea has been sold short.

Short Interest Ratio / Days to Cover

Fortrea has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Fortrea has recently increased by 11.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.01

News Sentiment

Fortrea has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for Fortrea this week, compared to 9 articles on an average week.

Search Interest

6 people have searched for FTRE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added Fortrea to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Fortrea insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,189.00 in company stock.

Percentage Held by Insiders

Only 0.38% of the stock of Fortrea is held by insiders.

FTRE Stock Analysis - Frequently Asked Questions

How have FTRE shares performed this year?

Fortrea's stock was trading at $18.65 on January 1st, 2025. Since then, FTRE stock has decreased by 74.5% and is now trading at $4.7650.

How were Fortrea's earnings last quarter?

Fortrea Holdings Inc. (NASDAQ:FTRE) posted its quarterly earnings data on Monday, May, 12th. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.09. The business had revenue of $651.30 million for the quarter, compared to analyst estimates of $609.63 million. Fortrea had a negative net margin of 29.43% and a positive trailing twelve-month return on equity of 2.84%.
Read the conference call transcript.

How do I buy shares of Fortrea?

Shares of FTRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Fortrea own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortrea investors own include AU Optronics (AUOTY), Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/07/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:FTRE
• CIK: 1965040
• Web: www.fortrea.com
• Phone: 877-495-0816
• Fax: N/A
• Employees: 15,500
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +237.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 8.73
• P/E Growth: 0.36
• Net Income: -$328.50 million
• Net Margins: -29.43%
• Pretax Margin: -27.83%
• Return on Equity: 2.84%
• Return on Assets: 1.06%

Debt

• Debt-to-Equity Ratio: 1.22
• Current Ratio: 0.97
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $2.70 billion
• Price / Sales: 0.15
• Cash Flow: $1.34 per share
• Price / Cash Flow: 3.32
• Book Value: $15.19 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 90,500,000
• Free Float: 90,156,000
• Market Cap: $402.73 million
• Optionable: Optionable
• Beta: 1.76